Skip to main content
Clinical Trials/NCT03886064
NCT03886064
Completed
Not Applicable

Scaling-up Packages of Interventions for Cardiovascular Disease Prevention in Selected Sites in Europe and Sub-Saharan Africa. SPICES Study Implementation Phase

University Hospital, Brest2 sites in 1 country583 target enrollmentApril 16, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiovascular Risk Factors
Sponsor
University Hospital, Brest
Enrollment
583
Locations
2
Primary Endpoint
Measurement of the non laboratory Interheart risk score
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Cardiovascular disease (CVD) is the leading cause of death in the world. 17.5 million people died in 2012 due to CVD (31% of all causes of death). In Europe more than 50% of deaths are due to CVD. The CVD mortality rate is higher in the lower socio-economic levels. Three quarters of CVD deaths occur in developing countries (LDCs). According to estimates in 2030, CVD will be responsible for more deaths than the sum of infectious, nutritional, maternal and perinatal diseases in developing countries. The lack of an adequate primary care network in developing countries limits the screening and treatment of people with CVRF. As a result, these people do not benefit from appropriate prevention, are diagnosed late and remain disabled or die at a young age, resulting in significant additional costs for families but also at the macroeconomic level.

Cardiovascular risk factor prevention measures (CVRF) have been shown to be effective. Interventions are possible on a large scale (policies against smoking and unfavorable eating habits, promoting physical activity, etc.). Actions are possible at the individual level, both in primary prevention (fight against the FDRCV) and secondary, where many treatments have proven their effectiveness. These interventions are effective and profitable from a macroeconomic point of view. It has been estimated that the cost for such interventions would not exceed 4% of health expenditure in developing countries and 1-2% in rich countries.

The World Health Organization (WHO) stresses the importance of the triad composed by the patient and his family, the community and health professionals. Results are possible only when these three components work together for the same purpose. Many studies show the benefit of people's involvement in care in rich and developing countries.

SPICES project builds on progress in HIV / AIDS treatment in sub-Saharan Africa (SSA) and chronic disease management through the Innovative Care for Chronic Conditions (ICCC Framework), WHO plan. With regard to HIV treatment, these interventions have proven to be effective and cost-effective in many SSA countries, both in terms of disease control and adherence. These data on communicable and infectious diseases seem to be transferable to non-communicable diseases.

These projects were born from the observation that the model of care of the rich countries (individual approach of the patient, centered on the hospital and the specialist with a regular clinical and paraclinical follow-up) could not be transposed to the developing countries, because the limitation of human, technical and financial resources. But also that this model was becoming more and more difficult to maintain in developed countries or resources become limited. New approaches need to be developed to increase the effectiveness of health systems.

A paradigm shift is needed to improve the control of CVD with greater cost-effectiveness.

The SPICES project incorporates the most up-to-date knowledge to improve the prevention and control of CVD in high-, middle- and low-income countries.

Rich countries and developing countries are therefore involved in the study. The selected sites are France, United Kingdom, Belgium, South Africa and Uganda.

Some main axes of the ICCC Framework will be developed in SPICES:

  • improve the efficiency of health professionals through the delegation of skills and appropriate training,
  • center care around the patient and his family and more generally his caregivers,
  • simplify the monitoring and treatment protocols,
  • support patients in their community and emphasize prevention, information and patient education.

A first step of observation in the various countries made it possible to make an inventory of fixtures and to target the most adapted interventions.

The following steps are the implementation of these interventions (delegation of skills, information campaign and screening, improve the availability of treatments, measure of strengthening of compliance, etc. ..) and their evaluation.

This study, carried out in France and integrated into the SPICES project, will test the best non-pharmacological interventions selected in the community and by the community.

Registry
clinicaltrials.gov
Start Date
April 16, 2019
End Date
January 5, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Within the general population, all persons over 18 years of age living or working in the country Center Bretagne (including Pays Pays Ouest Bretagne, Pleyben and Callac) with a moderate cardiovascular risk score based on the Interheart clinical risk score (score 9-15).

Exclusion Criteria

  • Pregnancy
  • Age under 18 years old
  • Patient in secondary cardiovascular prevention
  • Nobody living or working in Central Brittany (Pays Center Ouest Bretagne and Pays de Pleyben and Callac)
  • Low (\<9) or high cardiovascular risk score by Interheart score (\> 15).

Outcomes

Primary Outcomes

Measurement of the non laboratory Interheart risk score

Time Frame: 24 months

Comparison of the Non Laboratory Interheart risk average score between the two arms at 24 months. This scale is used to predict incident cardiovascular disease.This score is summed and is calculated from questions about family history, type of diet and sports activities.

Secondary Outcomes

  • Evaluation of the level of smoking(24 months)
  • Improvement of the diet(24 months)
  • BMI(24 months)
  • Measurement of the quality of life(24 months)
  • Level of physical activity(24 months)
  • Alcohol consumption(24 months)

Study Sites (2)

Loading locations...

Similar Trials